AAS
RYTM icon

Ameritas Advisory Services’s Rhythm Pharmaceuticals RYTM Stock Holding History

Ameritas Advisory Services’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,416
Closed -$231K – 920
2024
Q3 		$231K Buy
+4,416
New +$212K 0.01% 759
2023
Q2 		– Sell
-300
Closed -$6.09K – 2156
2023
Q1 		$6.09K Buy
+300
New +$7.53K ﹤0.01% 2092

Other funds holding RYTM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ameritas Advisory Services's RYTM Position: Q4 2024 in Review

Ameritas Advisory Services sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2024, closing a stake of 4,416 shares — an estimated $231K sold.

Ameritas Advisory Services first reported a position in RYTM in Q1 2023 and held it in 2 quarters. The position peaked at $231K in Q3 2024. 203 funds tracked by Wall St. Rank hold RYTM as of Q4 2024.

  • Ameritas Advisory Services reported no remaining Rhythm Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Ameritas Advisory Services sold 4,416 Rhythm Pharmaceuticals shares in Q4 2024, an estimated $231K.
  • Ameritas Advisory Services first reported a position in Rhythm Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Ameritas Advisory Services's Rhythm Pharmaceuticals position peaked at $231K in Q3 2024.
  • 203 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2024.

Based on Ameritas Advisory Services's 13F filing for Q4 2024, filed 15 Jan 2025.